Eris Lifesciences Ltd. Fundamental & Technical Research, Share Price Today

NSE : ERIS
NIFTY : Nifty 500
NIFTY SECTOR : Nifty MidSmall Healthcare

About Company

Eris Lifesciences Limited founded by Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.

Market Cap. ₹17,356 Cr.

52 Week - High/Low ₹1,594/816

P/E Ratio 201.05

P/B Ratio 6.88

Enterprise Value ₹16,319 Cr.

ROE % 12.65

RSI Value 90.54

EMA 50 1381.5

EMA 200 1387.8

Net Profit 300 Cr.

Net Profit 3year growth -14.52 Cr.

Net Profit 3 year (back) 351 Cr.

Debt to Equity 1.0 %

EPS Growth TTM -75.22 %

Current Ratio 0.83 %

100 Day SMA 1,330 Rs.

200 Day SMA 1,282 Rs.

21 Day SMA 1,326 Rs.

50 Day SMA 1,288 Rs.

Book Value 185 Rs.

EV/EBITDA Ratio 34

QoQ EPS Growth -94 %

QoQ Operating Profit Growth -30 %

QoQ Sales Growth -8 %

Sales Latest Quarter 390 Cr.

YoY Sales Growth 23 %

Market Cap. ₹17,356 Cr.

52 Week - High/Low ₹1,594/816

P/E Ratio 52.65

P/B Ratio 6.71

Enterprise Value ₹16,943 Cr.

ROE % 16.63

RSI Value 90.54

EMA 50 1381.5

EMA 200 1387.8

Net Profit 392 Cr.

Net Profit 3year growth -3.49 Cr.

Net Profit 3 year (back) 355 Cr.

Debt to Equity 1.06 %

EPS Growth TTM -14.78 %

Current Ratio 0.91 %

100 Day SMA 1,330 Rs.

200 Day SMA 1,282 Rs.

21 Day SMA 1,326 Rs.

50 Day SMA 1,288 Rs.

Book Value 190 Rs.

EV/EBITDA Ratio 18

QoQ EPS Growth -9 %

QoQ Operating Profit Growth -5 %

QoQ Sales Growth -2 %

Sales Latest Quarter 722 Cr.

YoY Sales Growth 50 %

Add Parameters

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages